花生过敏儿童表皮免疫治疗与安慰剂对照的PEPITES随机临床试验
该3期随机双盲安慰剂对照试验在5国31中心纳入356例4-11岁花生过敏儿童,每日使用含250μg花生蛋白贴片或安慰剂治疗12个月。花生贴片组应答率35.3% vs 安慰剂13.6%,差值21.7%(95%CI 12.4%-29.8%;P<.001),但未达到预设的95%CI下限≥15%的阳性标准。
要点
- 花生贴片组应答率35.3%,安慰剂组13.6%,差值21.7%有统计学意义。
- 未达到预设95%CI下限≥15%的阳性试验标准。
- 治疗相关不良事件主要为贴片应用部位反应,两组发生率分别为95.4%和89%。
核心结论
- 250μg花生贴片治疗12个月较安慰剂显著提高应答率差值21.7%,但未达到预设95%CI下限≥15%的阳性标准。
研究设计与样本
- 3期随机双盲安慰剂对照试验,2016年1月8日至2017年8月18日在5国31中心开展,纳入356例4-11岁无严重过敏反应史的花生过敏儿童。
主要发现
- 花生贴片组应答率35.3%,安慰剂组13.6%,差值21.7%(95%CI 12.4%-29.8%;P<.001)。
- 治疗相关不良事件发生率花生贴片组95.4%、安慰剂组89%,主要为贴片应用部位反应。
- 全因终止率花生贴片组10.5%、安慰剂组9.3%。
关键数值与推荐
- 基线诱发剂量≤10mg者,治疗后诱发剂量≥300mg为应答;基线>10至300mg者,治疗后≥1000mg为应答。
- 预设阳性标准为应答率差值95%CI下限≥15%。
临床怎么用
- 该花生贴片对4-11岁花生过敏儿童显示一定应答效果,但未达预设阳性标准,临床相关性待确定。
局限性
- 未达到预设95%CI下限标准,临床相关性尚不明确。
以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。
原文
IMPORTANCE: There are currently no approved treatments for peanut allergy. OBJECTIVE: To assess the efficacy and adverse events of epicutaneous immunotherapy with a peanut patch among peanut-allergic children. DESIGN, SETTING, AND PARTICIPANTS: Phase 3, randomized, double-blind, placebo-controlled trial conducted at 31 sites in 5 countries between January 8, 2016, and August 18, 2017. Participants included peanut-allergic children (aged 4-11 years [n = 356] without a history of a severe anaphylactic reaction) developing objective symptoms during a double-blind, placebo-controlled food challenge at an eliciting dose of 300 mg or less of peanut protein. INTERVENTIONS: Daily treatment with peanut patch containing either 250 μg of peanut protein (n = 238) or placebo (n = 118) for 12 months. MAIN OUTCOMES AND MEASURES: The primary outcome was the percentage difference in responders between the peanut patch and placebo patch based on eliciting dose (highest dose at which objective signs/symptoms of an immediate hypersensitivity reaction developed) determined by food challenges at baseline and month 12. Participants with baseline eliciting dose of 10 mg or less were responders if the posttreatment eliciting dose was 300 mg or more; participants with baseline eliciting dose greater than 10 to 300 mg were responders if the posttreatment eliciting dose was 1000 mg or more. A threshold of 15% or more on the lower bound of a 95% CI around responder rate difference was prespecified to determine a positive trial result. Adverse event evaluation included collection of treatment-emergent adverse events (TEAEs). RESULTS: Among 356 participants randomized (median age, 7 years; 61.2% male), 89.9% completed the trial; the mean treatment adherence was 98.5%. The responder rate was 35.3% with peanut-patch treatment vs 13.6% with placebo (difference, 21.7% [95% CI, 12.4%-29.8%; P < .001]). The prespecified lower bound of the CI threshold was not met. TEAEs, primarily patch application site reactions, occurred in 95.4% and 89% of active and placebo groups, respectively. The all-causes rate of discontinuation was 10.5% in the peanut-patch group vs 9.3% in the placebo group. CONCLUSIONS AND RELEVANCE: Among peanut-allergic children aged 4 to 11 years, the percentage difference in responders at 12 months with the 250-μg peanut-patch therapy vs placebo was 21.7% and was statistically significant, but did not meet the prespecified lower bound of the confidence interval criterion for a positive trial result. The clinical relevance of not meeting this lower bound of the confidence interval with respect to the treatment of peanut-allergic children with epicutaneous immunotherapy remains to be determined. TRIAL REGISTRATION: ClinicalTrials.gov Identifier: NCT02636699.
引用
- Fleischer DM, Greenhawt M, Sussman G, et al. Effect of Epicutaneous Immunotherapy vs Placebo on Reaction to Peanut Protein Ingestion Among Children With Peanut Allergy: The PEPITES Randomized Clinical Trial. JAMA. 2019. PMID: 30794314. doi:10.1001/jama.2019.1113
供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。